Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Symbiter
- Development stage
- Unknown
- Lead developer
- O.D. Prolisok
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Symbiter is a multiprobiotic dietary supplement formulated as "Symbiter acidophilic concentrated." It contains a combination of probiotic bacterial strains designed to restore and maintain the balance of gastrointestinal microflora. The product has been studied for its ability to prevent disbiotic changes and morphological alterations in the stomach associated with hypergastrinemia, hypoacidity/anacidity, atrophic gastritis, or long-term use of antisecretory drugs such as omeprazole. Its mechanism involves modulation of gut microbiota composition and function rather than direct pharmacological action on human molecular targets. It is recommended as an adjunct in complex therapy for acid-dependent diseases of the gastrointestinal tract to prevent dysbiosis and related gastric changes[1].
- Brand names
- SymbiterSymbiter acidophilic concentrated
- Other names
- multiprobiotic Symbitermultiprobiotic “Symbiter acidophilic concentrated”
Beyond the preview
Go deeper on Symbiter.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Symbiter.